Navigation Links
TetraQ and Q-Pharm form strategic alliance

TetraQ, the integrated preclinical contract research provider based at The University of Queensland, and Q-Pharm, a leading early phase clinical trial facility in Australasia, have formed a strategic alliance.

The alliance aims to enhance the delivery of bioanalytical services to clients in the biotechnology and pharmaceutical industries.

It is considered to be a positive development for the two businesses, which are both commercialisation enterprises of the University to give industry access to UQ's cutting-edge research resources and expertise.

TetraQ is a leading contract research organization that offers a broad range of preclinical services to the biopharmaceutical industry. A component of TetraQ's services includes bioanalytical services supporting clinical studies (including bioavailability/ bioequivalence and drug-drug interaction studies).

Q-Pharm is a Phase 1 clinical trial provider, servicing the early phase trial requirements of the pharmaceutical and biotech industries in Australia and around the world.

According to Q-Pharm CEO, Professor Wayne Hooper, the alignment of the two organisations at the interface of the preclinical and early phase clinical stages of the drug development pathway presented significant opportunities for capturing operational economies, co-marketing of services and cross-referral of potential clients.

"Since 2002, Q-Pharm has been one of Australia's foremost providers of bioanalytical services in support of clinical studies. When we decided to outsource our bioanalytical services to TetraQ the synergistic possibilities became more apparent," Professor Hooper said.

"We can expand our range of services to existing and future clients with TetraQ's involvement. It's a very positive step forward for both businesses as well as our clients."

TetraQ's Executive Director, Professor Maree Smith, also said there were advantages in a strategic alliance.

"TetraQ has a strong track record in fully-validated bioanalytical method development and sample analysis and we are recognised leaders in this area," Professor Smith said.

"TetraQ's GLP recognition and NATA ISO 17025 (R&D) accreditation has positioned TetraQ as the leading integrated preclinical service provider to the Australian biopharmaceutical industry. Q-Pharm is an industry leader in Phase 1 clinical trials so the alliance offers a consistent and reliable level of service."

The alliance was negotiated with the support of UniQuest Pty Limited, UQ's main commercialisation company.

UniQuest was also responsible for setting up TetraQ as the commercial arm of the Centre for Integrated Preclinical Drug Development at UQ and Q-Pharm as a joint venture with the Queensland Institute of Medical Research.

With their world-recognized credentials, both TetraQ and Q-Pharm have established enviable reputations for high quality services. Both organisations are committed to operating within quality frameworks that comply with the relevant industry-related international standards.

TetraQ was established in 2005 as the first contract research organization in Australia to provide integrated preclinical services to the global pharmaceutical and biotechnology industries. Its state-of-the-art facilities and equipment meet stringent quality and testing standards, and its bioanalytical work is accepted internationally for regulatory review, providing clients in the pharmaceutical and biotechnology industries with a high degree of assurance.

Emerging from UQ's Centre for Studies in Drug Disposition, Q-Pharm Pty Limited has grown rapidly in the past six years to become a major provider of Phase 1 clinical trial services to national and international clients. It also conducts Phase I clinical trials, pharmacokinetic studies and bioequivalence studies from its state-of-the-art facilities within the Royal Brisbane and Women's Hospital.


Contact: Rose-Marie Pennisi
Research Australia

Related medicine news :

1. TetraQ recognized for toxicology services
2. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
3. Martopia(R) Forms Strategic Alliance With Modern Healthcare Magazine
4. LehmanMillet Continues Expansion with Strategic Hires
5. Stille and Enova Form Strategic Partnership to Introduce Worlds Brightest LED Cordless Surgical Headlights Into Europe and Japan
6. Benjamin England, Former FDA Regulatory Counsel, to Testify on FDA Import Strategic Plan Before House Appropriations Subcommittee
7. Enters Strategic Collaboration To Support Microsoft HealthVault
8. Lumenis Ltd. Announces Senior Leadership Appointments Strengthening the Companys Strategic Businesses
9. Avantium and BP Extend Strategic Partnership
10. 40 86 Strategic Income Fund Declares Dividend
11. Medco, LabCorp Strike Strategic Agreement for Research on Personalized Medicine and Pharmacogenomics
Post Your Comments:
(Date:11/24/2015)... Port Richey, FL (PRWEB) , ... November 24, 2015 , ... ... it deems a growing epidemic as deaths from prescription opioids in the United States ... heroin and cocaine. In 2013 alone, opioids were involved in 37 percent of all ...
(Date:11/24/2015)... ... November 24, 2015 , ... Serenity Point Rehabilitation, a holistic treatment ... video interviews with some of the staff members at their recovery center. The videos ... as well as some of the things that make their recovery program so unique. ...
(Date:11/24/2015)... PALMYRA, Wis (PRWEB) , ... November 24, 2015 ... ... Process scholarship award at Cleveland University-Kansas City (CU-KC), in Overland Park, ... scholarship from Chiropractor and University President Carl S. Cleveland III on October 16. ...
(Date:11/24/2015)... N.Y. (PRWEB) , ... November 24, 2015 , ... Autism ... Tuesday, the global movement driven by social media and the generosity of people around ... then encourage their social media networks to give – and share the personal stories ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... of patented products, announces Fragrance by Marcelle, a cosmetic invention which offers a ... & Fragrance Manufacturing Market in the US is worth $3 billion annually," says ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... 24, 2015 Avery Biomedical Devices (ABD), manufacturer ... announce the appointment of Anders Jonzon , MD; ... Dr. Jonzon is a Physiologist ... Hospital, Uppsala University, Uppsala and Children,s Hospital, Karolinska, ... a fellow at the Cardiovascular Institute (UCSF). His research ...
(Date:11/24/2015)... 24, 2015  Ascendant Solutions, Inc. (Pink Sheets: ASDS ... of Directors has declared a special 1 percent stock dividend ... payable December 14, 2015, to shareholders of record December 7, ... additional shares of common stock. --> ... a strong endorsement of our confidence in Ascendant,s growth strategy ...
(Date:11/24/2015)... st  Scientific Assembly and Annual Meeting of the Radiological Society ... Chicago on Nov-29 th through Dec-4 ...  Scientific Assembly and Annual Meeting of the Radiological Society of ... Chicago on Nov-29 th through Dec-4 th , ... present its revolutionary whole body CZT digital SPECT/CT solution at the ...
Breaking Medicine Technology: